Elizabeth Miller, MD
Internal Medicine · St Louis Park, MNNPI 1659565489
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 9 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 3 manufacturers reported payments, led by Insmed, Inc. at 51.7% of the total.
Across 9 payments — averaging $27.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insmed, Inc.$127
- Pfizer$68
- Novo Nordisk$50
Across 22 payments — averaging $2317.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$51K
What the payments were for
- Food & beverage$24198%
- Education$42%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insmed, Inc. | 3 | $127 |
| Pfizer | 3 | $68 |
| Novo Nordisk | 3 | $50 |
How this compares
$245 in reported general payments places this provider in the 85th percentile of 1,924 internal medicine providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 220 | $208,404 |
| Breo ElliptaFluticasone/Vilanterol | 135 | $84,486 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 106 | $65,493 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 110 | $21,588 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 32 | $20,055 |
| Incruse ElliptaUmeclidinium Bromide | 36 | $13,678 |
| Wixela InhubFluticasone Propion/Salmeterol | 57 | $12,234 |
| Advair HfaFluticasone Propion/Salmeterol | 27 | $11,532 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $11,339 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 296 | $11,220 |
| Arnuity ElliptaFluticasone Furoate | 24 | $9,765 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 31 | $9,386 |
| Spiriva RespimatTiotropium Bromide | 13 | $8,343 |
| DuleraMometasone/Formoterol | 20 | $7,630 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 13 | $6,434 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in St Louis Park
- Gregory PolandRochester$494K
- Thomas MartensBrooklyn Center$158K
- Roy ChoMinneapolis$122K
- Kamran AfzalFridley$69K
- Ekta KapoorRochester$55K
- Luke SeaburgRochester$55K
- Robert PignoloRochester$52K
- Jaskanwal Deep SaraSaint Paul$50K
- Mustafa ArainMinneapolis$44K
- Noah WillifordMinneapolis$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.